Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is preparing for an IPO in Hong Kong, aiming to raise several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA technology [1] - Agna has developed a diverse range of RNA combinations and efficient drug delivery systems targeting infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from local government, Agna Biopharmaceuticals has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with several investment banks, including Bank of America, CICC, Jefferies, and JPMorgan, for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding the scale and timing still under discussion [1]
传阿格纳生物制药已选定投行秘密提交香港IPO申请 募资数亿美元
Zhi Tong Cai Jing·2025-11-06 07:29